Carbamazepine
Severe
Textbook
Decreased bictegravir plasma concentrations.
Should not be coadministered.
Source: G&G 14e · p1245-1266
Drug reference
Bictegravir
Antiretroviral
Also known as BIC
Antiretroviral
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- CarbamazepineSevereTextbookG&G 14e · p1245-1266
- RifamycinsSevereTextbookG&G 14e · p1245-1266
- St John S WortSevereTextbookG&G 14e · p1245-1266
- Aluminum HydroxideSevereDatabaseDDInter
Mechanism
Bictegravir is an integrase inhibitor (INSTI) that prevents the integration of viral DNA into the host cell genome. This action is critical because the integration of reverse-transcribed HIV DNA is a necessary step for the virus to replicate. By inhibiting the HIV-1 integrase enzyme, Bictegravir effectively blocks the HIV life cycle.
Indications
HIV infectionHIV-1 and HIV-2 infection in HIV-infected adults who are treatment naïve or suppressed on current antiretroviral therapy without known resistance to bictegravir, tenofovir, or emtricitabine
Dosing
- Adult
- 50 mg once daily, administered as a fixed-dose combination tablet containing bictegravir 50 mg, tenofovir alafenamide (TAF) 25 mg, and emtricitabine 200 mg.
- Max dose
- 50 mg once daily (as part of a fixed-dose combination)
Pharmacokinetics
Half-life
17.3
Protein binding
>99%
Metabolism
CYP3A4, UGT1A1
Side effects
Common
NauseaDiarrheaHeadacheRashIncreased total bilirubinIncreased serum creatinine
Drug interactions
Rifamycins
Severe
Textbook
Decreased bictegravir plasma concentrations.
Should not be coadministered.
Source: G&G 14e · p1245-1266
St John S Wort
Severe
Textbook
Decreased bictegravir plasma concentrations.
Should not be coadministered.
Source: G&G 14e · p1245-1266
Aluminum Hydroxide
Severe
Database
Clinical effect not specified
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Attapulgite
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium Acetate
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium Carbonate
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium Glubionate Anhydrous
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium Gluconate
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium Glycerophosphate
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Antimicrobial resistance — clinical roadmap
MOHFW · Infectious Diseases · 2012
Hepatitis B — chronic infection
INASL · Gastroenterology · 2023
Antiretroviral therapy for HIV
NACO · Infectious Diseases · 2018
Skin and soft tissue infections
IDSA · Infectious Diseases · 2010
Hepatitis B — chronic infection
EASL · Gastroenterology · 2025
Other Antiretroviral drugs
Ask House about Bictegravir
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team